Emine Zengin

Emine Zengin

Auto-generated profile, based on publicly available information

Emine Zengin

Department of Pediatric Hematology&Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MYM. Akif Yesilipek
M. Akif Yesilipek
VUVedat Uygun
Vedat Uygun
AKAlphan Kupesiz
Alphan Kupesiz
GKGulsun Karasu
Gulsun Karasu
GOGulyuz Ozturk
Gulyuz Ozturk
AAAli Bülent Antmen
Ali Bülent Antmen

17 March 2020 in Turkish Journal of Hematology
Verified
Journal Article
Open access
AYAyça Koca Yozgat
Ayça Koca Yozgat
GLGöksel Leblebisatan
Göksel Leblebisatan
SASinan Akbayram
Sinan Akbayram
SÖSimge Çınar Özel
Simge Çınar Özel
ZKZeynep Karakaş
Zeynep Karakaş
NÖNamık Yaşar Özbek
Namık Yaşar Özbek
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.

30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
BSBerkay Saraymen
Berkay Saraymen
SMSabahattin Muhtaroğlu
Sabahattin Muhtaroğlu
MKMustafa Köker
Mustafa Köker
NSNazan Sarper
Nazan Sarper
EZEmine Zengi̇n
Emine Zengi̇n
MÇMustafa Çeti̇n
Mustafa Çeti̇n
Glanzmann thrombasthenia (GT) is a rare autosomal recessively inherited bleeding disorder characterized by the quantitative (type 1 and type 2) or qualitative (type 3) deficiency in platelet membrane glycoprotein (GP) IIb/IIIa (CD41a/CD61) fibrinogen receptors. In type 1, 2 and 3, CD41a/CD61 expression is 5%, 5-20% and above 20%, respectively. In this study, diagnosis of GT was confirmed and subgroups were identified in 32 Turkish patients by flow cytometry analysis. CD41a/CD61 expression levels in platelet-rich plasma (PRP) obtained from peripheral venous EDTA blood samples were analyzed with a BD FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). GT subgroup analysis was performed by counting 50000 events in the BD FACSDiva Software v6.1.3 program of the instrument. In the present study, in blood samples of 32 patients from 23 family with GT and 22 healthy controls, co-expression levels of CD41a and CD61 in PRP was analyzed. 12 out of 23 families were consistent with type 1 GT (52.2%), 4 were consistent with type 2 GT (17.4%) and 7 were consistent with type 3 GT (30.4%). Especially due to consanguineous marriages, GT with various glycoprotein levels may be detected. As a result of the flow-cytometry analysis of the present study with the highest GT patient population in Turkey, type 1 GT patients were the most common subgroup. In the determination of the GT subgroups; especially in the detection of type 3 GT, flow cytometry is the most sensitive glycoprotein analysis method. In addition to light transmission aggregometry, CD41a/CD61 study by flow-cytometer confirms diagnosis when mutation analysis cannot be performed.

12 April 2021 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
YEYucel Erbilgin
Yucel Erbilgin
ÖHÖzden Hatırnaz
Özden Hatırnaz
ICIsmail Can
Ismail Can
SFSinem Firtina
Sinem Firtina
FKFulya Kucukcankurt
Fulya Kucukcankurt
MSMuge Sayitoglu
Muge Sayitoglu

1 August 2019 in Leukemia Research
Verified
Journal Article
Closed access
YEYucel Erbilgin
Yucel Erbilgin
SFSinem Firtina
Sinem Firtina
SMSevcan Mercan
Sevcan Mercan
ÖHÖzden Hatırnaz
Özden Hatırnaz
SKSerap Karaman
Serap Karaman
MSMuge Sayitoglu
Muge Sayitoglu

19 July 2021 in Platelets
Verified
Journal Article
Closed access
MKMustafa Köker
Mustafa Köker
NSN Sarper
N Sarper
CAC Albayrak
C Albayrak
BZB Zulfikar
B Zulfikar
EZE Zengin
E Zengin
VJV Jallu
V Jallu
Glanzmann thrombasthenia (GT) is a rare autosomal recessive bleeding disorder characterized by impaired platelet aggregation due to defects in integrin αIIbβ3, a fibrinogen receptor. Platelet phenotypes and allelic variations in 28 Turkish GT patients are reported. Platelets αIIbβ3 expression was evaluated by flow cytometry. Sequence analyzes of ITGA2B and ITGB3 genes allowed identifying nine variants. Non-sense variation effect on αIIbβ3 expression was studied by using transfected cell lines. 3D molecular dynamics (MDs) simulations allowed characterizing structural alterations. Five new alleles were described. αIIb:p.Gly423Asp, p.Asp560Ala and p.Tyr784Cys substitutions impaired αIIbβ3 expression. The αIIb:p.Gly128Val substitution allowed normal expression; however, the corresponding NM_000419.3:c.476G>T variation would create a cryptic donor splicing site altering mRNA processing. The β3:p.Gly540Asp substitution allowed αIIbβ3 expression in HEK-293 cells but induced its constitutive activation likely by impairing αIIb and β3 legs interaction. The substitution alters the β3 I-EGF-3 domain flexibility as shown by MDs simulations. GT variations are mostly unique although the NM_000419.3:c.1752 + 2 T > C and NM_000212.2:c.1697 G > A variations identified in 4 and 8 families, respectively, might be a current cause of GT in Turkey. MD simulations suggested how some subtle structural variations in the β3 I-EGF domains might induce constitutive activation of αIIbβ3 without altering the global domain structure.